TME Pharma N.V. (PA:ALTME) — Market Cap & Net Worth
Market Cap & Net Worth: TME Pharma N.V. (ALTME)
TME Pharma N.V. (PA:ALTME) has a market capitalization of $7.34 Million (€6.28 Million) as of September 24, 2026. Listed on the PA stock exchange, this France-based company holds position #27882 globally and #487 in its home market, demonstrating a 9.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TME Pharma N.V.'s stock price €0.11 by its total outstanding shares 94091417 (94.09 Million). Also see TME Pharma N.V. assets under control for a full breakdown of the balance sheet.
TME Pharma N.V. Market Cap History: 2016 to 2026
TME Pharma N.V.'s market capitalization history from 2016 to 2026. Data shows change from $219.27 Billion to $11.88 Million (-62.53% CAGR). Also see TME Pharma N.V. (ALTME) cash flow conversion for how efficiently the company converts equity into cash flow.
TME Pharma N.V. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TME Pharma N.V.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest TME Pharma N.V. stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
434.22x
TME Pharma N.V.'s market cap is 434.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $219.27 Billion | $83.00K | -$10.75 Million | 2641804.02x | N/A |
| 2017 | $63.32 Billion | $234.00K | -$5.38 Million | 270589.76x | N/A |
| 2019 | $5.80 Billion | $154.00 | -$861.00K | 37683872.16x | N/A |
| 2020 | $5.60 Billion | $35.00 | -$10.40 Million | 160111209.10x | N/A |
| 2021 | $2.33 Billion | $33.00K | -$14.45 Million | 70705.77x | N/A |
| 2023 | $25.30 Million | $17.00K | -$6.74 Million | 1488.27x | N/A |
| 2024 | $8.25 Million | $19.00K | -$5.72 Million | 434.22x | N/A |
Competitor Companies of ALTME by Market Capitalization
Companies near TME Pharma N.V. in the global market cap rankings as of September 24, 2026. Review tangible net worth ratio of TME Pharma N.V. to assess the quality of the company's equity after excluding intangible assets.
Key companies related to TME Pharma N.V. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
TME Pharma N.V. Historical Marketcap From 2016 to 2026
Between 2016 and today, TME Pharma N.V.'s market cap moved from $219.27 Billion to $ 11.88 Million, with a yearly change of -62.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €11.88 Million | +65.64% |
| 2025 | €7.17 Million | -13.07% |
| 2024 | €8.25 Million | -67.39% |
| 2023 | €25.30 Million | -79.13% |
| 2022 | €121.23 Million | -94.80% |
| 2021 | €2.33 Billion | -58.36% |
| 2020 | €5.60 Billion | -3.44% |
| 2019 | €5.80 Billion | -42.94% |
| 2018 | €10.17 Billion | -83.94% |
| 2017 | €63.32 Billion | -71.12% |
| 2016 | €219.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of TME Pharma N.V. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.34 Million USD |
| MoneyControl | $7.34 Million USD |
| MarketWatch | $7.34 Million USD |
| marketcap.company | $7.34 Million USD |
| Reuters | $7.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as m… Read more